Patents by Inventor Annyt Bhattacharyya

Annyt Bhattacharyya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of Acalabrutinib
    Patent number: 11345706
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: May 31, 2022
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Crystalline forms of Ponatinib hydrochloride
    Patent number: 11072620
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 27, 2021
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Crystalline Forms of Acalabrutinib
    Publication number: 20210130360
    Abstract: The present invention provides crystalline forms of Acalabrutinib, Specific crystalline forms provided by the present invention include Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea.
    Type: Application
    Filed: August 23, 2018
    Publication date: May 6, 2021
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya, Wancheng Guo, Jingda Zhang, Kun Cheng, Kangying Li
  • Crystalline form of Eluxadoline
    Patent number: 10822309
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 3, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Crystalline form of Olaparib
    Patent number: 10662178
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: May 26, 2020
    Assignee: Apotex Inc.
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Crystalline Forms of Ponatinib Hydrochloride
    Publication number: 20200095255
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Application
    Filed: June 15, 2018
    Publication date: March 26, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Crystalline Form of Eluxadoline
    Publication number: 20200079740
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Crystalline form of Eluxadoline
    Patent number: 10487059
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: November 26, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Crystalline form of selexipag
    Patent number: 10407396
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 10, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Crystalline Form of Olaparib
    Publication number: 20190233400
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Application
    Filed: January 30, 2019
    Publication date: August 1, 2019
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Crystalline Form of Selexipag
    Publication number: 20190144397
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Crystalline Form of Eluxadoline
    Publication number: 20190092734
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Application
    Filed: September 24, 2018
    Publication date: March 28, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Crystalline forms of ibrutinib
    Patent number: 10183024
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 22, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Crystalline Forms of Ibrutinib
    Publication number: 20180153895
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 7, 2018
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Solid Forms of Mirabegron
    Publication number: 20170291882
    Abstract: Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 12, 2017
    Inventors: Allan W. Rey, Annyt Bhattacharyya, Jenny L. Gerster, Sammy Chris Duncan, Mohammed Abdul Raheem, Fan Wang, Stuart P. Green
  • Method of controlled alcoholysis and regeneration of a borohydride
    Patent number: 7601797
    Abstract: Methods of controlled hydrolysis/alcoholysis and regeneration of a borohydride are disclosed. Examples of the present invention show that hydrolysis of sodium borohydride or lithium borohydride with dilute acid provides simultaneous generation of H2 and boric acid for recycling. Other examples of the present invention show methods for regenerating a borohydride by reacting an aluminum hydride to a borate compound to provide a regenerated borohydride.
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: October 13, 2009
    Assignee: Purdue Research Foundation
    Inventors: P. Veeraraghavan Ramachandran, Debasis Hazra, Bhimapaka China Raju, Venkatram Reddy Mereddy, Annyt Bhattacharyya
  • Method of controlled alcoholysis and regeneration of a borohydride
    Publication number: 20050255024
    Abstract: Methods of controlled hydrolysis/alcoholysis and regeneration of a borohydride are disclosed. Examples of the present invention show that hydrolysis of sodium borohydride or lithium borohydride with dilute acid provides simultaneous generation of H2 and boric acid for recycling. Other examples of the present invention show methods for regenerating a borohydride by reacting an aluminum hydride to a borate compound to provide a regenerated borohydride.
    Type: Application
    Filed: May 10, 2005
    Publication date: November 17, 2005
    Inventors: P. Ramachandran, Debasis Hazra, Bhimapaka Raju, Venkatram Reddy Mereddy, Annyt Bhattacharyya